Kura Oncology (NASDAQ:KURA) Raised to “Strong-Buy” at Lifesci Capital

Lifesci Capital upgraded shares of Kura Oncology (NASDAQ:KURA) to a strong-buy rating in a research note released on Tuesday morning, Zacks.com reports.

Several other equities analysts have also commented on the stock. StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Thursday, August 22nd. Wedbush restated an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a report on Friday, August 9th. HC Wainwright restated a “buy” rating and issued a $32.00 price objective on shares of Kura Oncology in a report on Monday, August 12th. JMP Securities reiterated a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a report on Monday, August 12th. Finally, Stifel Nicolaus lowered shares of Kura Oncology from a “buy” rating to a “hold” rating and reduced their target price for the stock from $26.00 to $19.00 in a report on Monday, October 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Kura Oncology has a consensus rating of “Moderate Buy” and a consensus target price of $28.83.

Kura Oncology Stock Performance

Kura Oncology stock opened at $17.51 on Tuesday. The firm has a 50 day simple moving average of $19.34 and a 200-day simple moving average of $20.09. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.94 and a quick ratio of 14.94. Kura Oncology has a 1-year low of $7.52 and a 1-year high of $24.17. The stock has a market cap of $1.34 billion, a price-to-earnings ratio of -7.85 and a beta of 0.84.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.04. During the same quarter last year, the business earned ($0.53) earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis. On average, analysts expect that Kura Oncology will post -2.46 EPS for the current year.

Institutional Investors Weigh In On Kura Oncology

Hedge funds and other institutional investors have recently modified their holdings of the company. nVerses Capital LLC acquired a new stake in shares of Kura Oncology in the 3rd quarter valued at $25,000. SG Americas Securities LLC acquired a new stake in shares of Kura Oncology in the 1st quarter valued at $110,000. Quarry LP acquired a new stake in shares of Kura Oncology in the 2nd quarter valued at $196,000. Saxon Interests Inc. purchased a new position in shares of Kura Oncology in the 1st quarter valued at $201,000. Finally, Entropy Technologies LP purchased a new position in shares of Kura Oncology in the 1st quarter valued at $218,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.